Junshi Biosciences announces approval for the new adjunctive drug application of Toripalimab (subcutaneous injection) for the first-line treatment of HER2-expressing urothelial carcinoma.
Junshi Biosciences announces approval for the new adjunctive drug application of Toripalimab (subcutaneous injection) for the first-line treatment of HER2-expressing urothelial carcinoma.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in